Abstract Library

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#4073 Comparative targeted NGS analysis between solid and liquid biopsies in GEP-NET: A pilot study

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a broad clinical variability. Genetic profile could be a striking resource to respond to prognostic and treatment purposes. Sequencing of circulating tumor DNA (ctDNA) from liquid biopsy (LB) has been proposed as a less invasive alternative to solid biopsy (SB).

Conference:

Presenting Author:

Authors: Gagliardi I, Borges de Souza P, Martiradonna M, Rossi L, Albertelli M,

Keywords: Genetic profile, Liquid biopsy, Solid biopsy, GEP-NET, ctDNA,

#3680 18F-FMISO PET in metastatic neuroendocrine neoplasms – A pilot study

Introduction: The phenomenon of peripheral 68Ga-DOTATATE avidity without central avidity (a so-called “donut") has been observed in neuroendocrine neoplasm (NEN) lesions. There has been speculation as to whether this region of non-avidity reflects hypoxia, de-differentiated disease or other causes. The presence of hypoxia has significant prognostic and therapeutic implications, and was evaluated in these lesions using 18F-FMISO PET/CT.

Conference:

Presenting Author: Chan D

Authors: Chan D, Conner A, Pavlakis N, Bailey E, Aslani A,

Keywords: hypoxia, 18F-FMISO, 68Ga-DOTATATE, PET/CT, biomarker,

#3417 SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,

#3288 Not waving but drowning?

Introduction: The disruptive impact COVID19 has had on cancer care availability and resources may yet have far-reaching consequences, physically and mentally, for those with neuroendocrine Cancer.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Jervis N

Authors: Jervis N,

Keywords: support, unmet needs, psychosocial care, impact of COVID,